Maze Therapeutics (NASDAQ:MAZE) Upgraded by Leerink Partnrs to Strong-Buy Rating

Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.

A number of other research firms have also commented on MAZE. JPMorgan Chase & Co. initiated coverage on Maze Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $30.00 price target on the stock. Guggenheim initiated coverage on Maze Therapeutics in a research report on Tuesday. They set a “buy” rating and a $19.00 price target on the stock. Finally, Leerink Partners initiated coverage on Maze Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $28.00 price target on the stock.

Maze Therapeutics Stock Performance

MAZE stock opened at $10.57 on Tuesday. Maze Therapeutics has a 1-year low of $10.08 and a 1-year high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.